Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_assertion type Assertion NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_head.
- NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_assertion description "[By automatic imaging analyses, the AMACR immunostaining intensity and percentage in prostatic adenocarcinomas were also significantly higher than those in benign prostatic tissue (105.9 versus 16.1 for intensity, 45.7% versus 0.02% and 35.03% versus 4.64% for percentage, respectively).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_provenance.
- NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_assertion evidence source_evidence_literature NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_provenance.
- NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_assertion SIO_000772 15330799 NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_provenance.
- NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_assertion wasDerivedFrom befree-2016 NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_provenance.
- NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_assertion wasGeneratedBy ECO_0000203 NP457350.RA2LBrxVDE2e6oYSRSIsZo1_ngtaxNJ6eaRcODH5CKtJM130_provenance.